GALNT1 emerges as a potential therapeutic target in breast cancer.
J Cancer Res Clin Oncol. 2026 Mar 25;152(3):74. doi: 10.1007/s00432-026-06448-2.PMID: 41880012 Free PMC article.
RESULTS: GALNT1 was significantly upregulated in primary breast cancer as well as multiple other malignancies. In vitro experiments demonstrated that GALNT1 promoted breast cancer cell proliferation, migration, and O-glycosylation. Immunofluorescence staining reveal …
Transforming Growth Factor-beta Drives Epithelial Mesenchymal Transition and Reduces Synthesis of Unelaborated O-GalNAc Glycans in Breast Cancer Cells.
J Histochem Cytochem. 2026 Mar-Apr;74(2):193-214. doi: 10.1369/00221554261416994. Epub 2026 Feb 28.PMID: 41764140 Free PMC article.
The effect of TGF-beta1 on synthesis of unelaborated Tn antigen was explored using Helix pomatia agglutinin (HPA) labelling. TGF-beta1 treatment induced morphological changes, resulting in an elongated, mesenchymal-like phenotype, and a reduction of epithelial marke …
Deletion of Core 1 β3GalT-specific molecular chaperone (Cosmc) in murine intestinal epithelia leads to major alterations in glycocalyx and tumorigenesis.
J Biol Chem. 2026 Feb 25;302(4):111319. doi: 10.1016/j.jbc.2026.111319. Online ahead of print.PMID: 41759737 Free PMC article.
Expression of such glycans is under control of Cosmc (C1GalT1C1) that encodes a key ER molecular chaperone required for formation of active T-synthase, a Golgi enzyme that modifies the Tn antigen (GalNAcalpha1-Ser/Thr/Tyr - CD175) to generate a Core 1 O-glycan. We p …
Blocking glycan production by targeting GALNT7 for prostate cancer therapy.
Expert Opin Ther Targets. 2026 Feb;30(2):87-92. doi: 10.1080/14728222.2026.2619761. Epub 2026 Jan 23.PMID: 41556382 No abstract available.
Liposome-Based Potential Vaccines Platforms that Are Noncytotoxic.
ChemistryOpen. 2026 Jan;15(1):e202500530. doi: 10.1002/open.202500530.PMID: 41521398 Free PMC article.
Synthetic vaccines represent a promising avenue in cancer immunotherapy by promoting targeted immune responses. Liposomal technologies have further advanced synthetic vaccinology by enabling the efficient delivery of tumor-associated carbohydrate antigens. ...In this preli …
Higher-Energy Collisional Dissociation Mass Spectrometry Fragmentation Enables Distinguishing O-GlcNAc from Tn Antigen in Cancer Cells.
J Am Soc Mass Spectrom. 2026 Feb 4;37(2):491-504. doi: 10.1021/jasms.5c00378. Epub 2026 Jan 10.PMID: 41518202
One representative example is O-linked beta-N-acetylglucosamine (O-GlcNAc) and O-linked alpha-N-acetylgalactosamine (Tn antigen). Traditional biochemistry approaches used in separating O-GlcNAc- and Tn antigen-modified peptides mainly include chemical …
Diagnostic Potential of Tn-MUC1 in Breast Cancer: A Novel Immunohistochemical Marker Reflecting Tumor Progression.
Lab Invest. 2026 Mar;106(3):106070. doi: 10.1016/j.labinv.2025.106070. Epub 2026 Jan 6.PMID: 41506350
Recently, a novel epitope-defined antibody (MUC1-Tn antigen epitope-defined antibody [MUC1-Tn ED Ab]) that specifically recognizes the Tn-MUC1 antigen was developed. ...In multilesion analysis, cytoplasmic Tn-MUC1 expression was rarely detected in nonneoplastic area …
A novel method for Tn antigen detection based on chemoenzymatic targeted labelling and CuAAC click chemistry.
Chem Commun (Camb). 2026 Jan 29;62(8):2599-2602. doi: 10.1039/d5cc05398f.PMID: 41496556
The Tn antigen is a key tumor-associated antigen and a promising cancer biomarker. However, its low abundance poses great challenges for sensitive detection. We developed a novel approach that integrates B3GNT6-mediated Tn-specific labelling, click chemistry, …
Synthetic Multivalent Tn Antigen Elicits Valency-Dependent IgG Antibody Production.
Bioconjug Chem. 2026 Jan 21;37(1):20-30. doi: 10.1021/acs.bioconjchem.5c00444. Epub 2025 Dec 16.PMID: 41401309
The Tn antigen is an attractive target for cancer vaccine development. In this study, we report the efficacies of dendrimer-based multivalent Tn antigens to elicit profound antibody generation in mice, in a subtype-specific manner. Multivalency of the Tn …
Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment.
Front Immunol. 2025 Nov 26;16:1660852. doi: 10.3389/fimmu.2025.1660852. eCollection 2025.PMID: 41383589 Free PMC article. Review.
BACKGROUND: Abnormal protein glycosylation is a key feature of tumors. Among the modifications, Tn antigen (GalNAcalpha1-Ser/Thr) and its sialylated derivative, STn antigen (Neu5Acalpha2-6GalNAcalpha1-O-Ser/Thr), are prominent tumor-associated carbohydrate antigens. …
Inga kommentarer:
Skicka en kommentar